Rufinamide clinical studies

Rufinamide has been studied primarily for its effectiveness in treating seizures associated with Lennox-Gastaut syndrome, a severe form of epilepsy. Clinical trials involving patients with this condition showed that Rufinamide significantly reduced seizure frequency compared to placebo. These studies also monitored safety, noting common side effects like fatigue, dizziness, and nausea. Overall, the research supports Rufinamide as an important option for managing difficult-to-control seizures, demonstrating both its efficacy and tolerability in patients with Lennox-Gastaut syndrome.